Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Indivior eyes cannabis disorder treatment

By Brian Buntz | June 8, 2021

IndiviorBilling itself as the “world leader in opioid addiction treatment,” Indivior (INDV.L) is looking to diversify into treating cannabis use disorder.

The North Chesterfield, Va.–The headquartered company will spend $30 million upfront to acquire Aelis Farma for development rights for AEF0117, an investigational drug that blocks the CB1 cannabinoid receptor in the brain. In addition to cannabis use disorder, the experimental drug could also potentially treat cannabis-induced psychosis.

AEF0117 has shown promise in Phase 1 and Phase 2 trials. AEF0117 is a first-in-class signaling-specific inhibitor, according to Indivior.

Aelis stands to rake in an additional $100 million if the drug candidate meets additional milestones, including succeeding in a planned Phase 2b study.

Indivior, like many other companies with opioid-based products, has faced significant legal pressures in the U.S. as the country grapples with an ongoing opioid epidemic.

In a statement, Indivior CEO Mar Crossley explained that cannabis is one of the most widely used drugs globally and the third most commonly used substance of abuse in the U.S. after alcohol and tobacco. There are, however, “no FDA-approved medications for cannabis-related disorders, which are complex and concerning,” Crossley said. “AEF0117 is the most advanced new chemical entity under investigation in the clinic and potentially represents a unique opportunity to address a growing unmet public health need.”


Filed Under: Drug Discovery and Development
Tagged With: Indivior
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
GSK
GSK to invest £1 billion on infectious disease research
CB Therapeutics
CB Therapeutics hires new business development lead

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50